Pharmaceuticals

TJ DaRenTang USD

TJ DaRenTang USD released FY2026 Q1 earnings on April 29 After-Market (SGT), actual revenue USD 219.2 M, actual EPS USD 0.0795

TJ DaRenTang USD to Release FY2026 Q1 Earnings on April 30 After-Market (SGT)

TJ DaRenTang USD released FY2025 Q4 earnings on March 30 During-Market (SGT), actual revenue USD 178.31 M, actual EPS USD -0.0039

TJ DaRenTang USD released FY2025 annual earnings on March 30 During-Market SGT, actual revenue USD 689.24 M (forecast USD 901.09 M), actual EPS USD 0.3882

TJ DaRenTang USD to Release FY2025 Earnings on March 31 During-Market SGT, Forecast Revenue SGD 900.36 M

Tangrensheng Xinxin Pharmaceutical Factory Obtains Registration Certificate for Loxoprofen Sodium Gel Patch

TJ DaRenTang USD released FY2025 Q3 earnings on October 30 Pre-Market (SGT), actual revenue USD 143.18 M, actual EPS USD 0.0412

TJ DaRenTang USD released FY2025 9 Months Earnings on October 30 Pre-Market (SGT), actual revenue USD 510.18 M, actual EPS USD 0.387

TJ DaRenTang USD to Release FY2025 Q3 Earnings on October 31, Pre-Market SGT

TJ DaRenTang USD released FY2025 Semi-Annual Earnings on August 14 During-Market (SGT), actual revenue USD 367.23 M, actual EPS USD 0.3463

TJ DaRenTang USD released FY2025 Q2 earnings on August 14 During-Market (SGT), actual revenue USD 166.65 M, actual EPS USD 0.2782

DatRenTang's 2025 H1 Report: Net Profit Surges 193.08%

TJ DaRenTang USD to Release FY2025 Semi-Annual Earnings on August 15, 2025 (SGT)

Ta-ren Tang's Tongmai Yangxin Pills Recommended in Chinese Medicine Guideline

TJ DaRenTang USD released FY2025 Q1 earnings on April 29 After-Market SGT, actual revenue USD 200.35 M, actual EPS USD 0.0674

TJ DaRenTang USD to Release FY2025 Q1 Earnings Report on April 30 After-Market SGT

TJ DaRenTang USD released FY2024 annual earnings on March 28 After-Market (SGT), actual revenue USD 1.015 B (forecast USD 1.652 B), actual EPS USD 0.4014

TJ DaRenTang USD released FY2024 Q4 earnings on March 28 After-Market SGT, actual revenue USD 232.32 M, actual EPS USD 0.2546

TJ DaRenTang USD to release FY2024 earnings on March 31 After-Market SGT, forecasted revenue 1.613 B SGD

TJ DaRenTang USD released FY2024 9 Months earnings on October 30 After-Market SGT, actual revenue USD 796.42 M, actual EPS USD 0.1547

SingtelMBeCW260730

Abundance

Geely MB ePW261005

Asiatic

HSI 28000MBePW260629

Alibaba MB eCW260703

Teho

P-Nova Short MSSG-1X USy

NKY 55000MBePW260911

NKY 52000MBePW260612

600329

TJ DaRenTang released its 2025 semi-annual report, with revenue of 2.651 billion yuan, a year-on-year decrease of 33.15%; net profit attributable to the parent company was 1.928 billion yuan, a year-on-year increase of 193.08%. This was mainly due to the transfer of 12% equity in Tianjin Sike, resulting in a post-tax net gain of 1.308 billion yuan. The net profit excluding non-recurring items was 596 million yuan, a year-on-year decrease of 5.93%. After excluding the impact of investment income from joint ventures, the net profit attributable to the parent company excluding non-recurring items increased by 12.86% year-on-year

Zhitong

DRTG

TJ DaRenTang announced its semi-annual performance, with a net profit attributable to the parent company of 1.928 billion yuan, a year-on-year increase of 193.08%

According to DRTG, the "Traditional Chinese Medicine Diagnosis and Treatment Guidelines for Coronary Microvascular Disease," led by the Chinese Association of Traditional Chinese Medicine and jointly formulated by national authoritative experts, has been released. Tongmai Yangxin Wan, a product under DRTG, has received a "strong recommendation" level recognition

TJ DaRenTang: Tongmai Yangxin Pills strongly recommended in the Traditional Chinese Medicine Diagnosis and Treatment Guidelines for Coronary Microvascular Disease

TJ DaRenTang announced that the company expects to achieve a net profit attributable to the owners of the parent company of RMB 1.84 billion to RMB 2 billion for the first half of 2025, an increase of RMB 1.182 billion to RMB 1.342 billion compared to the same period last year, representing a year-on-year increase of 180% to 204%. It is expected that the net profit attributable to the owners of the parent company, excluding non-recurring gains and losses, will be RMB 560 million to RMB 620 million for the first half of 2025, a decrease of RMB 73.83 million to RMB 13.83 million compared to the same period last year, representing a year-on-year decrease of 12% to 2%

TJ DaRenTang: Expected net profit in the first half of 2025 to increase by 180%-204% year-on-year

According to the Zhitong Finance APP, DRTG disclosed its first-quarter report for 2025, showing that the company achieved revenue of 1.455 billion yuan, a year-on-year decrease of 30.22%; net profit attributable to the parent company was 374 million yuan, a year-on-year decrease of 3.38%; and net profit excluding non-recurring items was 376 million yuan, a year-on-year decrease of 0.04%. Basic earnings per share were 0.49 yuan

TJ DaRenTang announced its first-quarter performance, with a net profit attributable to the parent company of 374 million yuan, a year-on-year decrease of 3.38%

TJ DaRenTang plans to sell its 12% stake in Tianjin Shike Pharmaceutical Co., Ltd. for RMB 1.623 billion to increase cash inflow. In this transaction, TJ DaRenTang will transfer 4.6% equity to Haleon (China) for RMB 622 million and 7.4% equity to Haleon CH SARL for RMB 1.001 billion. After the transaction is completed, TJ DaRenTang will no longer hold shares in Tianjin Shike, and it is expected to impact the company's current investment income by approximately RMB 1.54 billion

TJ DaRenTang plans to sell 12% of its shares in Tianjin Shike for 1.623 billion yuan to increase cash inflow

DRTG released its 2024 annual performance, with a net profit attributable to the parent company of 2.229 billion yuan, a year-on-year increase of 125.94%

Yinhua CSI Chinese Medicine ETF

DRTG released its 2024 annual performance, with a net profit attributable to the parent company of 2.229 billion yuan, a year-on-year increase of 125.94%

TJ DaRenTang USD(T14.SG)

TJ DaRenTang announced its semi-annual performance, with a net profit attributable to the parent company of 1.928 billion yuan, a year-on-year increase of 193.08%

TJ DaRenTang: Tongmai Yangxin Pills strongly recommended in the Traditional Chinese Medicine Diagnosis and Treatment Guidelines for Coronary Microvascular Disease

TJ DaRenTang: Expected net profit in the first half of 2025 to increase by 180%-204% year-on-year

TJ DaRenTang announced its first-quarter performance, with a net profit attributable to the parent company of 374 million yuan, a year-on-year decrease of 3.38%

TJ DaRenTang plans to sell 12% of its shares in Tianjin Shike for 1.623 billion yuan to increase cash inflow

DRTG released its 2024 annual performance, with a net profit attributable to the parent company of 2.229 billion yuan, a year-on-year increase of 125.94%